The role of histamine as a newly recognized sympathetic neurotransmitter has been presented previously, and its postsynaptic effects greatly depended on the activities of sympathetic nerves. Cardiac sympathetic nerves become overactivated under acute myocardial ischemic conditions and release neurotransmitters in large amounts, inducing ventricular arrhythmia. Therefore, it is proposed that cardiac sympathetic histamine, in addition to norepinephrine, may have a significant arrhythmogenic effect. To test this hypothesis, we observed the release of cardiac sympathetic histamine and associated ventricular arrhythmogenesis that was induced by acute ischemia in isolated mouse hearts. Mast cell-deficient mice (MCDM) and histidine decarboxylase knockout (HDC -/-) mice were used to exclude the potential involvement of mast cells. Electrical field stimulation and acute ischemia-reperfusion evoked chemical sympathectomy-sensitive histamine release from the hearts of both MCDM and wild-type (WT) mice but not from HDC -/-mice. The release of histamine from the hearts of MCDM and WT mice was associated with the development of acute ischemia-induced ventricular tachycardia and ventricular fibrillation. The incidence and duration of induced ventricular arrhythmias were found to decrease in the presence of the selective histamine H 2 receptor antagonist famotidine. Additionally, the released histamine facilitated the arrhythmogenic effect of simultaneously released norepinephrine. We conclude that, under acute ischemic conditions, cardiac sympathetic histamine released by overactive sympathetic nerve terminals plays a certain arrhythmogenic role via H 2 receptors. These findings provided novel insight into the pathophysiological roles of sympathetic histamine, which may be a new therapeutic target for acute ischemia-induced arrhythmias. Online address: http://www.molmed.org doi: 10.2119/molmed.2011. 00225 and that sympathetic nerve terminals release HA upon appropriate stimulation (16, (18) (19) (20) . On the basis of these findings, we proposed HA to be a newly recognized sympathetic neurotransmitter. Furthermore, the postsynaptic effects of sympathetic HA have been found to be positively related to the firing activities of sympathetic nerves (19) . The overactivation of cardiac sympathetic nerves in ischemic hearts, as reported in previous studies, further correlates with ischemiainduced ventricular arrhythmias (11) (12) (13) 21, 22) . Therefore, it is rational to speculate that sympathetic HA, in addition to norepinephrine (NE), is also released and plays certain pathophysiological roles in ischemia-induced ventricular arrhythmias.
In the present study, mast cell-deficient mice (MCDM) and HDC knockout (HDC -/-) mice were used to test the aforementioned hypothesis and to further clarify the pathophysiological roles of cardiac sympathetic HA.
MATERIALS AND METHODS

Animals
MCDM (Wads c-kit mutant mice) were provided by Dr. Xiang Gao of Model Animal Research Center of Nanjing University (Nanjing, China (pH 7.4) and quickly cleared of surrounding excess tissues. The aorta of each heart was cannulated with a flanged stainlesssteel needle, and the heart was perfused with KH solution at 37°C and constant pressure (100 cm H 2 O). The solution contained 1 μmol/L atropine and 0.1 μmol/L desipramine and was equilibrated with 95% O 2 and 5% CO 2 . Only hearts with an initially stable sinus rhythm were considered for further experiments. The coronary effluents were collected every 5 min, and coronary HA and NE overflows were measured simultaneously by high-performance liquid chromatography with electrochemical detection, as previously described (23) . Hearts were weighed after the experiments for result standardization, quickly frozen with liquid nitrogen and stored at -80°C before cyclic adenosine 3′,5′-cyclic monophosphate (cAMP) assaying.
Electrical Field Stimulation
Electrical field stimulation (EFS) experiments were performed according to previous studies (21) . After perfusion with KH solution and equilibration for 30 min, two stainless steel paddles were apposed to the heart with their stimulating surface parallel to the interventricular septum. EFS was performed for 60 s at 2, 4 or 8 Hz with pulse duration of 1 ms and voltage of 5 V, generated by PowerLab/8SP (ADInstruments). Each tissue was stimulated at one of the selected frequencies only.
Ischemia/Reperfusion and Electrocardiogram Recording
After 30-min stabilization, hearts were subjected to 10-, 20-, or 30-min stop-flow normothermic global ischemia followed by a 30-min reperfusion. Surface electrocardiograms were obtained using two electrodes with one attached to the aortic cannula and the other to the apex of the left ventricle (recorded online with recording frequency of 4 kHz, analyzed with PowerLab/8SP). According to previous studies (24) , the electrode was purpose-built with a small (approximately 1 mm) bare silver ball to achieve steady contact between the electrode and the heart, ensuring minimal movement occurred. The coronary HA overflow was measured and the incidence and duration of reperfusion arrhythmias were calculated according to the Lambeth Conventions (25) .
In experiments to exhaust endogenous HA, 50 mg/kg α-fluoromethylhistidine (αFMH) was injected intraperitoneally 2 h before the study (26) . To explore the effects of the antagonists, the reagents were applied 10 min before ischemia and continuously perfused until the end of the 30-min reperfusion. Vehicles were used as controls. To explore the effects of exogenous HA and/or NE, the corresponding reagents were applied for 5 min. The surface ECGs were recorded soon after the application of HA and/or NE for a duration of 30 min.
Sympathetic Denervation
To denervate sympathetic nerves, 6-hydroxydopamine (6-OHDA) was dissolved in saline containing 0.1% ascorbic acid, and mice were treated as previously mentioned (16) . Briefly, 6-OHDA was injected through the caudal vein with 50 mg/kg on d 1 and 100 mg/kg 6-OHDA on d 7. For the control experiments, solutions containing only 0.1% ascorbic acid in saline were used. Mice were sacrificed for study 7 d after the final injection.
cAMP Assay
To measure myocardial cAMP levels, each sample was homogenized mechanically in frozen PBS (pH = 7.4) with a mechanical homogenizer. The homogenate was thawed and centrifuged at 5,000g at room temperature for 15 min, and the 100-mL aliquots of supernatant were subjected to the assay. Levels of cAMP were determined by enzyme-linked immunosorbent assay (Biotrak EIA, Amersham Pharmacia Biotech, Bucks, UK).
Chemicals
Atenolol, biotinylated secondary antibody, famotidine, FITC-conjugated secondary antibody, HA, HA antibody, 6-hydroxydopamine and NE were from Sigma. DβH antibody was from Incstar. Texas Red-conjugated antibody was from Molecular Probes (Eugene, OR, USA). Tryptase antibody was from Abcam (Cambridge, UK). α-Fluoromethylhistidine was provided by C Kamei (Okayama University, Japan).
Data Analysis
Values were expressed as mean ± standard deviation (SD), and statistical differences between groups were determined by the χ 2 test, Student t test or analysis of variance (ANOVA) followed by Student-Newman-Keuls t test where necessary. A value of P < 0.05 was considered statistically significant.
All supplementary materials are available online at www.molmed.org.
RESULTS
Morphological Identification
The coat color of heterozygous MCDM is black with white spots, whereas that of homozygous MCDM is pure white with eyes remaining black (27) . The staining of tryptase, a specific marker of mast cells, showed that heart sections from WT and HDC -/-mice expressed a number of mast cells (Figures 1A 1 , C 1 ), but none were found in the hearts of the homozygote of MCDM ( Figure 1B 1 ). HA-like immunopositive signals were found to be present in SCG neurons of the same WT mice and homozygote of MCDM ( Figures 1A 3 , B 3 ), but were absent in the HDC -/-mice ( Figure 1C 3 ). . Experiments were repeated in three mice from each strain, and five sections of heart or SCG from each one mouse were observed. Scale bar, 50 μm.
R E S E A R C H A R T I C L E
Effect of EFS or Acute Ischemia on
Coronary HA and NE Overflows Table 1 shows the basic parameters of isolated hearts from the three phenotypes of mice and indicates that there were no significant differences among the groups. As shown in Figure 2A 1 , EFS frequencydependently evoked HA release from Langendorff-perfused hearts of WT mice and MCDM. No significant differences in HA overflow were observed between the two groups. A 10-min period of acute global stop-flow ischemia induced a similar amount of HA release from isolated hearts of WT mice and MCDM after reperfusion ( Figure 2B 1 ) . The HA concentration in coronary effluents peaked in the first 5 min of reperfusion and decreased thereafter. Neither EFS nor ischemia evoked significant HA release in HDC -/-mice. However, coronary NE overflow induced by EFS or acute ischemia exhibited a similar pattern among the three mouse strains, being slightly higher in HDC -/-mice (Figures 2A 2 , B 2 ) .
Effect of Ischemia Time on Coronary HA and NE Overflows
To explore coronary HA and NE overflows upon acute or prolonged global ischemia, different time courses of stop- D 1 8 : 1 -9 , 2 0 1 2 flow (10, 20 or 30 min) were applied. As shown in Figure 3 , no significant differences were observed in the coronary HA (A) and NE (B) overflows in the first 5 min of reperfusion between WT mice and MCDM after 10 min of ischemia. However, when the time courses of stopflow were increased to over 20 min, the coronary HA and NE overflows of WT mice group were significantly greater than those of the MCDM group.
| H E E T A L . | M O L M E
A R R H Y T H M O G E N I C E F F E C T O F S Y M P A T H E T I C H I S T
Effect of 6-Hydroxydopamine on EFS or Acute Ischemia Evoked Coronary HA and NE Overflows
The coronary HA and NE overflows induced by EFS in WT mice and MCDM were almost entirely eliminated when mice were pretreated with 6-OHDA (Figures 4A 1 , A 2 ) . Similarly, pretreatment with 6-OHDA also eliminated acute ischemia-induced coronary HA and NE overflows ( Figures 4B 1 , B 2 ) .
Effect of Acute Ischemia on Ventricular Arrhythmogenesis
Representative ECG recordings from one WT mouse, MCDM or HDC -/-mouse after reperfusion are shown in Figure 5A . Ischemia for 10 min resulted in the occurrence of ventricular tachycardia (VT) and/or ventricular fibrillation (VF) in WT mice and MCDM groups after reperfusion. The rhythm became irregular during the first minute of reperfusion and gradually returned to regular sinus rhythm thereafter. In the HDC -/-mice group, the incidence and duration of VT and/or VF induced by ischemia was markedly reduced (Figures 5B, C) . Furthermore, after pretreatment with αFMH, the coronary HA overflow in MCDM after ischemia was markedly decreased (see Supplementary Figure S1 ) with the incidence and duration of VT and/or VF reduced to the level of the HDC -/-mice group (Figures 5B, C) .
Effects of Atenolol and Famotidine on Acute Ischemia-Induced Ventricular Arrhythmogenesis
To explore the effects of atenolol and famotidine on the incidence and duration of VT and/or VF, selective β 1 adreno ceptor antagonist atenolol (1 μmol/L) and selective H 2 receptor antagonist famotidine (100 nmol/L) were used either alone or in combination. When used alone, each of these two drugs only marginally (not significantly) reduced the incidence of VT and/or VF but markedly shortened the VT and/or VF duration (72.5% decrease in WT mice, 63.2% decrease in MCDM; P < 0.05). However, when used in combination, both the incidence and duration of VT and/or VF were significantly reduced ( Figures 6A, B) . Furthermore, these two drugs affected neither the coronary HA overflow ( Figure 6C ) nor the other basic parameters of perfused isolated hearts, including the initial normal sinus rhythm and the coronary NE overflow (data not shown).
Effects of Exogenous HA and NE on Ventricular Arrhythmogenesis
Exogenous application of either HA (1 μmol/L) or NE (1 μmol/L) independently induced ventricular arrhythmogenesis in WT mice and MCDM isolated hearts with a respective incidence of 100% (n = 5). When used in combination, synergism was observed between the arrhythmogenic effect of HA and NE. Specifically, the durations of VT and/or VF induced by NE together with HA were markedly prolonged (219% increase in WT mice, 234% increase in MCDM), which was longer than the sum of VT and/or VF durations induced by HA and NE independently ( Figures 7A, B) .
Effect of Famotidine on the Cardiac cAMP Level in Isolated Mouse Hearts After Reperfusion
At the end of the 30-min reperfusion, the cardiac cAMP levels in hearts of the three strains of mice were all significantly increased compared with the cor- responding preischemia control groups. Pretreatment with famotidine markedly reduced the increased cardiac cAMP levels in WT mice and MCDM groups, but did not significantly affect the increased cAMP level in the HDC -/-mice group (Figure 8 ).
R E S E A R C H A R T I C L E
DISCUSSION
Cardiac mast cells are a well-acknowledged source of cardiac HA (28) . However, the morphological results from the present study consistently show that HA is also present in the SCGs of MCDM and absent in HDC -/-mice. This strongly indicates that sympathetic HA is synthesized and stored independently of mast cells and is in support of previous work, which found HA present in cardiac sympathetic axons and varicosities projected from SCGs (16) . Therefore, the MCDM model is ideal for studying the functions of cardiac sympathetic HA, and the HDC -/-mice, which do not express HA, are also appropriate as negative controls.
| H E E T A L . | M O L M E D 1 8 : 1 -9 , 2 0 1 2 A R R H Y T H M O G E N I C E F F E C T O F S Y M P A T H E T I C H I S T
The results of previous studies have shown that with appropriate stimulation, such as EFS (21) and acute ischemia (11, 13, 21) , cardiac sympathetic nerve terminals are activated, triggering neurotransmitter release. In the present study, such stimulations also evoked mast cell-independent HA overflow. To clarify the origin of HA, we performed chemical sympathectomy with 6-OHDA and achieved cardiac sympathectomy, as indicated by diminished NE release. HA release was found to be sensitive to 6-OHDA pretreatment, firmly suggesting a sympathetic neural origin.
The NE release induced by EFS or ischemia in the present study is in accordance with previous reports (11) (12) (13) 21) and remained high in HDC -/-mice, which confirmed the activation of cardiac sympathetic nerve terminals. The slightly (but not significantly) increased coronary NE overflow in HDC -/-mice may be due to the lack of endogenous HA required to activate sympathetic presynaptic H 3 receptors, which in turn exert an inhibitory effect on NE release (11) (12) (13) 16 Figure S2 ) was because prolonged ischemia (>10 min) caused significant mast cell activation and severe adverse cellular injury. This step not only releases HA but also triggers NE, one of the most important arrhythmogenic factors, released via the local renin system (30) . Mast cell activation and severe cellular injury would significantly complicate interpretation of the present results. Therefore, to simplify the experimental model and focus on the pathophysiological roles of cardiac sympathetic HA, we investigated short-lived acute myocardial ischemia using a 10-min ischemia period, during which time barely any biochemical and cellular changes were observed. Further research is recommended to clarify the nature of cardiac HA release in protracted myocardial ischemia.
Cardiac H 2 receptors mediate positive chronotropic and inotropic effects (9, (31) (32) (33) . In the present study, the selective H 2 receptor antagonist famotidine was found to slightly decrease the incidence of ischemia-induced ventricular arrhythmia and markedly reduced the duration. This result was evidently a postsynaptic effect, since famotidine did not affect sympathetic HA release. This result is in accordance with previous studies, in which certain H 2 receptor antagonists have been found to exhibit a cardiac protecting effect in ischemic heart diseases, including antiarrhythmia (6, 7, 9, 34) . Moreover, results in the present study confirm the mediating role of the H 2 receptor (35, 36) and indicate the therapeutic potential of its antagonist in treatment of ischemia-induced ventricular arrhythmias. Furthermore, our experiments show that famotidine did not fully reduce cardiac cAMP to the preischemia level. One possible reason for this is that NE, which is released simultaneously, plays an important role in triggering the rise of cardiac cAMP levels, via postsynaptic β 1 adrenoreceptors and in inducing positive chronotropic and in- otropic effects. This is the basis for the clinical use of β adrenoreceptor antagonists in the treatment of ischemia-induced arrhythmias (37) . The finding that the selective β 1 adrenoreceptor antagonist atenolol used independently exhibited a similar antiarrhythmic effect to famotidine but when used in combination, a stronger antiarrhythmic effect was observed, confirms the hypothesis that cardiac sympathetic HA facilitates the arrhythmogenic effect of NE. This finding is consistent with the results of previous research, which showed that the postsynaptic effect of NE is facilitated by sympathetic HA in guinea pig vas deferens (19) and is because both the β 1 adrenoreceptor (38) and the H 2 receptor (35) are Gs protein coupled receptors, sharing the same second messenger.
While the present study has investigated the relationship between HA and ischemia-induced arrhythmogenesis, HA is only one of the arrhythmogenic factors, and the arrhythmogenic roles of many other factors (such as renin, angiotensin, endothelins and so on) still require clarification. Furthermore, although the cardiac protection effect of H 2 receptor antagonists is reasonably well established from previous investigations (28, 39) and the present study, the origin of cardiac HA after prolonged ischemia is complicated, and the relationship between the effects of HA from different origins remains uncertain. This issue is likely to prove a valuable area of research for future investigations in this field.
CONCLUSION
In summary, the present study has demonstrated for the first time that cardiac sympathetic HA plays a certain arrhythmogenic role in acute myocardial ischemia, via postsynaptic H 2 receptors. These findings provide considerable insight into the pathophysiological function of cardiac sympathetic HA and H 2 receptors and offer novel experimental evidence in the search for therapeutic targets to cure acute ischemia-induced arrhythmias.
